Stocks · News reference
SL Science Highlighted The Filing Of A New Drug Master File With The U.S. FDA Covering Exosomes Derived From Gamma Delta T Cells
SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ:SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapies, today highlighted the filing of
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 12:19 PM
- Checked
- Aug 27, 2026, 12:19 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
SL Science Announces Publication Of Peer-Reviewed Article In 'Biomedicines' Outlining A Rigorous Development Framework For γδ T Cell Therapy In Glioblastoma
Glioblastoma a common and aggressive primary brain cancer in adults. Beyond reviewing existing literature, the paper outlines the specific clinical trial designs, biological measurements, and testing conditions required
Read original at benzingaSL Science Presents Benefits Of Gamma Delta T Cells In Eliminating Glioblastoma In Preclinical Studies At The 2026 World Congress Of Basic And Clinical Pharmacology
SL Science Holding Limited (NASDAQ:SLBT) ("SL Science" or the "Company"), a biotechnology company developing next-generation immune cell therapies, today announced its successful exhibition and
Read original at benzinga